X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.
A man wearing a suit with a halo hovering over his hand.

We hope you enjoy this excerpt from Litigation Daily, the exclusive source for sharp commentary on mega court battles, winning strategies and the issues that obsess elite litigators. Law.com subscribers can sign up for The AmLaw Litigation Daily newsletter here. Anyone else can click here to subscribe.   

My colleague Charles Toutant is up with a fascinating look at how the public perception of pharmaceutical companies changed over the past year and the worries that those changes have sparked among the members of the plaintiffs bar who regularly litigate against drug makers.

It’s worth digging into the full report, but here are my quick takeaways: The Harris Poll reported in February that 62% of Americans gave positive ratings to the pharmaceutical industry, nearly double the 32% positive rating drug companies received just before the pandemic took hold in the U.S. in January of last year. Another pollster, Data for Progress, reported in late March that 56% of Americans had a favorable view of pharmaceutical companies, and 24% had an unfavorable view—a swift and dramatic change from its November 2019 poll finding a 48% favorable view and 38% unfavorable of the same group. A March report by RepTrak said the industry’s reputation boost “had to do with their key role in getting us through the pandemic.”

Want to continue reading?
Become a Free ALM Digital Reader.

Benefits of a Digital Membership:

  • Free access to 1 article* every 30 days
  • Access to the entire ALM network of websites
  • Unlimited access to the ALM suite of newsletters
  • Build custom alerts on any search topic of your choosing
  • Search by a wide range of topics

*May exclude premium content
Already have an account?

Ross Todd

Ross Todd is the Editor/columnist for the Am Law Litigation Daily. He writes about litigation of all sorts. Previously, Ross was the Bureau Chief of The Recorder, ALM's California affiliate. Contact Ross at [email protected] On Twitter: @Ross_Todd.

More from this author

Law Firms Mentioned

 
Reprints & Licensing
Mentioned in a Law.com story?

License our industry-leading legal content to extend your thought leadership and build your brand.

Federal Tax LitigationBook

This law book offers an insider's perspective on both the legal issues and practical considerations involved in handling a federal tax controversy.

Get More Information
 
 

ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.